Novartis and The Max Foundation announce cancer care partnership

Novartis has announced a new partnership with The Max Foundation that will offer free cancer care for patients in lower-income countries.

The CMLPath to Care scheme will support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukaemia (CML), gastrointestinal tumours and other rare cancers in nearly 70 countries.

This represents an evolution from the organisations' previous Glivec International Patient Assistance Program, which was launched in 2002 and provided Glivec therapy at no cost to approximately 75,000 people.

Under the new scheme, The Max Foundation will assume responsibility for delivering treatment to patients, including supply chain management, while Novartis will provide funding and drug donation support. The agreement runs until the first quarter of 2021, with an option to extend.

Once again, Glivec will be the main therapy provided to recipients, while in a subset of countries second-line Tasigna therapy will also be available for approved indications.

Bruno Strigini, chief executive officer of Novartis Oncology, said: "CMLPath to Care renews and extends our unique collaboration with The Max Foundation and builds on the strengths of both organisations to better serve these patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.